STAT3 and familial pancreatic carcinoma: Moreover, the orally available direct STAT3 inhibitor napabucasin (BBI608) was approved by the United States Food and Drug Administration (FDA) for the treatment of two cancers, including gastric/gastroesophageal junction (GEJ) cancer and pancreatic cancer in 2016.